We are a specialty pharmaceutical company involved in the manufacturing, distribution and marketing of our novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. The Company’s technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). Both therapies have been decades in the making at institutions such as the Pennsylvania State University Medical School at Hershey, University of Chicago, State University of New York, and Multiple Sclerosis Center at UCSF. These efforts were pioneered by leading immunologists: Dr. Nicholas Plotnikoff, Dr. Ronald Herberman, Dr. Bernard Bihari, Ian S. Zagon, Dr. Jill Smith, Patricia McLaughlin, and Dr. Jaquelyn McCandless.
We have spent the last two years acquiring regulatory approval in emerging and developing nations for LDN marketed under the brand name Lodonal™. Lodonal™ is a highly innovative immunotherapy for the treatment of autoimmune diseases, HIV/AIDS, opportunistic infections, cancer and a range of other serious diseases. Our proprietary Opiate and T Cell Receptor technology exploits the power of the body’s own immune system to find and kill diseased cells.
Among developing nations, African countries bear the greatest disease burden in the world. The biggest health threats are communicable diseases such as HIV/AIDS, malaria, and tuberculosis. In addition to that burden developing nations are now experiencing, there is an additional burden of a rise in non-communicable diseases, including cancer, diabetes and inflammatory disease. Even when drugs are available in developing nations, many of the drugs are too expensive, too complex to administer, cause significant side effects, and require regular medical testing to be used safely. LDN can be an answer to all of those problems; LDN is safe, easy to administer and affordable. Existing treatment for Cancer, HIV/AIDS, and autoimmune disease suppress the body’s immune system while Lodonal (LDN) is an immune modulator used to rebalance or stimulate the immune system to improve the quality of life for people effected with these diseases. The biggest issue with cancer in developing nations is that you cannot administer chemotherapy to people that already have a comprised immune system. We have created a platform of affordable medications, that are easy to administer. We expect to begin the process of seeking regulatory approval for MENK/OGF in emerging and developing nations in early 2015.
Expanding immune stimulation to revolutionize the fight against cancers, autoimmune & infectious diseases
- Stimulating the body’s immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, inflammatory disease, autoimmune disease and other chronic infectious diseases.
- Our immune therapy technology platform has shown its potential to establish a new paradigm to prevent and treat these life-altering diseases, with validating efficacy data from all Phase I and Phase II clinical trials for such diseases as HIV/AIDS, pancreatic cancer, Crohn’s Disease, liver disease, fibromyalgia and herpes, etc.
- Clinical Trials have shown that LDN activates the immune system and increases production of CD4, T cells, Natural killer (NK) cell numbers and NK cell activity and lymphocyte activated CD8 numbers.